Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Gene Therapy
Ascidian to ‘rewrite’ RNA for Roche
by Rowan Walrath
June 24, 2024
| A version of this story appeared in
Volume 102, Issue 19
Roche has tapped the biotech start-up Ascidian Therapeutics to discover and develop RNA exon–editing medicines. Ascidian “rewrites” RNA by editing exons, parts of genes that form the nucleic acid, with the goal of fixing genetic mutations that cause diseases. Roche will pay Ascidian $42 million up front and a potential $1.8 billion in milestone payments to create such medicines for undisclosed neurological targets.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2025 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X